Stockscreener 앱 받기
7.61
6.44%
0.47
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Best data tools to analyze Tango Therapeutics Inc. stockMarket Activity Summary & Capital Efficiency Focused Strategies - newser.com
Detecting price anomalies in Tango Therapeutics Inc. with AIWeekly Risk Report & Reliable Intraday Trade Alerts - newser.com
Developing predictive dashboards with Tango Therapeutics Inc. dataJuly 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Tango Therapeutics Inc. stock trendline breakdownIPO Watch & Reliable Entry Point Alerts - newser.com
Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $10.50 Average PT from Analysts - Defense World
Will Tango Therapeutics Inc. benefit from macro trendsChart Signals & Reliable Price Action Trade Plans - newser.com
Is a relief rally coming for Tango Therapeutics Inc. holders2025 Market Overview & Fast Moving Trade Plans - newser.com
Market reaction to Tango Therapeutics Inc.’s recent newsBull Run & Free Expert Approved Momentum Trade Ideas - newser.com
Real time alert setup for Tango Therapeutics Inc. performance2025 Major Catalysts & Safe Capital Growth Plans - newser.com
Tango Therapeutics' (TNGX) Sell (E+) Rating Reaffirmed at Weiss Ratings - MarketBeat
Historical volatility pattern of Tango Therapeutics Inc. visualizedMarket Activity Summary & Fast Moving Market Watchlists - newser.com
Real time social sentiment graph for Tango Therapeutics Inc.Earnings Growth Summary & Daily Entry Point Trade Alerts - newser.com
Tango To Present At The 2025 SITC Annual Meeting — Will New Insights Make Waves? - RTTNews
Regression analysis insights on Tango Therapeutics Inc. performanceTrade Ideas & Daily Oversold Bounce Ideas - newser.com
Is Tango Therapeutics Inc. building a consolidation base2025 Major Catalysts & Breakout Confirmation Trade Signals - newser.com
Tango Therapeutics’ SWOT analysis: biotech stock’s promise amid clinical trials By Investing.com - Investing.com South Africa
Tango Therapeutics’ SWOT analysis: biotech stock’s promise amid clinical trials - Investing.com UK
Tango Therapeutics to Present First Clinical Data from - GlobeNewswire
First clinical data: TNG260 — Tango Therapeutics presents Phase 1/2 results at SITC Nov 7 - Stock Titan
Building trade automation scripts for Tango Therapeutics Inc.Weekly Stock Analysis & Daily Growth Stock Investment Tips - newser.com
Published on: 2025-10-05 03:22:51 - newser.com
Piper Sandler Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $11 - 富途牛牛
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
Multi factor analysis applied to Tango Therapeutics Inc.Bull Run & Fast Momentum Entry Tips - newser.com
How to use Fibonacci retracement on Tango Therapeutics Inc.Weekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Tango Therapeutics Hits New 52-Week High of $8.79, Marking Major Milestone - Markets Mojo
Healthcare veteran David Wilkinson to join Tango as chief financial officer - MarketScreener
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN
Published on: 2025-09-30 04:30:06 - newser.com
Published on: 2025-09-30 03:51:20 - newser.com
Major Shareholder Sells Off Tango Therapeutics Stock in Multi-Million Dollar Deal! - TipRanks
Tango Therapeutics (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 500,000 Shares - MarketBeat
Tango Therapeutics, Inc. $TNGX Position Reduced by Goldman Sachs Group Inc. - Defense World
Tango Therapeutics Hits New 52-Week High at $8.56 - Markets Mojo
0.22%
자본화:
|
볼륨(24시간):